hábit Labs · Devolve Corp
Certificate of Analysis
FOR RESEARCH PURPOSES ONLY. This material is supplied for in-vitro laboratory research by qualified researchers. It shall not be used for human therapeutic purposes and is not for human or veterinary consumption. It is not a drug, supplement, cosmetic, food additive, or medical device.
Product identification
ProductTirzepatide 50mg
DescriptionDual GIP/GLP-1 receptor agonist
Lot numberTZP-2604-A
Release dateApr 2026
Molecular formulaC₂₂₅H₃₄₈N₄₈O₆₈
AppearanceLyophilized powder
Storage−20 °C, protected from light
ManufacturerDevolve Corp d/b/a hábit · Ft. Lauderdale, FL
Analytical results
Identity (LC-MS)Confirmed✓ Pass
Purity (HPLC)99.4%✓ Pass
Mass spec (MW)4,813.5✓ Pass
Endotoxin (LAL)<0.5 EU/mg✓ Pass
Residual solventsWithin spec✓ Pass
AppearanceWhite cake✓ Pass
Each Tirzepatide vial ships with a batch-specific COA documenting peptide identity by LC-MS, purity by reverse-phase HPLC (≥99%), mass spec confirmation against MW 4,813.5, endotoxin assay by LAL, residual solvent screening, and physical appearance. Third-party verification by an ISO-17025 laboratory.
Specifications
CAS2023788-19-2
Molecular formulaC₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight4,813.5 g/mol
FormLyophilized, sealed under nitrogen
Purity≥99% by HPLC, mass spec single peak
Endotoxin<0.5 EU/mg
Available dosages50mg
Lot prefixTZP-
Storage & handling
Lyophilized: −20°C, 24 months unopened. Reconstituted: 2–8°C, use within 30 days. Reconstitute with bacteriostatic water for injection; swirl, do not shake. Avoid repeated freeze-thaw.